Recent Company News

• 07:41 AM ET Feb 23, 2026
  

  Transcript Intelligence: Almirall Q4 Earnings Themes

• 07:41 AM ET Feb 23, 2026
  

  Transcript Intelligence: Almirall Q4 Earnings Guidance

• 07:41 AM ET Feb 23, 2026
  

  Transcript Intelligence: Almirall Q4 Earnings Q&A

• 02:57 AM ET Feb 23, 2026
  

  StreetAccount Summary - European pre-market trading update

• 01:09 AM ET Feb 23, 2026
  

  Almirall reports FY net income €46.2M vs FactSet €47.0M [12 est, €42-54.3M] (€13.42, 0.00)

• 03:53 AM ET Feb 19, 2026
  

  StreetAccount Summary: EU stocks reaching new 52-week highs/lows (123 total)

• 02:09 AM ET Jan 29, 2026
  

  Almirall announces approval of Seysara in China for treatment of moderate-to-severe acne (€12.46, 0.00)

• 04:12 AM ET Jan 20, 2026
  

  StreetAccount Summary - Trading higher/lower: EU mid-morning

• 01:39 AM ET Jan 20, 2026
  

  BNP Paribas Exane upgrades FDR.SM; downgrades ALM.SM, COL.SM, EBRO.SM, and MEL.SM

• 02:05 AM ET Jan 15, 2026
  

  Almirall to begin Phase III Study "LumiNE" evaluating Lebrikizumab in nummular eczema (€13.22, 0.00)